Skip to main content
Premium Trial:

Request an Annual Quote

Qiagen to Distribute Celera Respiratory Panel

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Qiagen will distribute a multiplex respiratory pathogen test manufactured by Celera, under an agreement announced today by the firms.

The molecular diagnostic test is the next-generation version of Qiagen's ResPlex II assay for detecting respiratory pathogens. The assay detects 19 different pathogens associated with respiratory infections and is designed for use on the LiquiChip 100 and 200 instrument platforms, which are based on Luminex's technology.

Under terms of the deal, Qiagen has exclusive worldwide rights to distribute the multiplex test kit, which Celera will manufacture. Qiagen expects to seek regulatory approval for the panel in the US and Europe.

"Celera's significant experience in the development and manufacturing of molecular diagnostic products is a very valuable resource and this relationship can accelerate our effort to further expand our molecular diagnostic solution portfolio," Qiagen CEO Peer Schatz said in a statement.

Financial and further terms of the agreement were not disclosed.

The Scan

Booster for At-Risk

The New York Times reports that the US Food and Drug Administration has authorized a third dose of the Pfizer-BioNTech SARS-CoV-2 vaccine for people 65 and older or at increased risk.

Preprints OK to Mention Again

Nature News reports the Australian Research Council has changed its new policy and now allows preprints to be cited in grant applications.

Hundreds of Millions More to Share

The US plans to purchase and donate 500 million additional SARS-CoV-2 vaccine doses, according to the Washington Post.

Nature Papers Examine Molecular Program Differences Influencing Neural Cells, Population History of Polynesia

In Nature this week: changes in molecular program during embryonic development leads to different neural cell types, and more.